Cargando…
A Drug‐Drug Interaction Study to Evaluate the Effect of TAS‐303 on CYP3A Activity in the Small Intestine and Liver
TAS‐303 (4‐piperidinyl 2,2‐diphenyl‐2‐[propoxy‐1,1,2,2,3,3,3‐d(7)] acetate hydrochloride) is a novel selective noradrenaline reuptake inhibitor being developed for the treatment of stress urinary incontinence. An in vitro study and a physiologically based pharmacokinetic model simulation showed that...
Autores principales: | Kumagai, Yuji, Fujita, Tomoe, Maeda, Mika, Sasaki, Yoshinobu, Nagaoka, Makoto, Huang, Jinhong, Takenaka, Toru, Kawai, Masaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318569/ https://www.ncbi.nlm.nih.gov/pubmed/32026490 http://dx.doi.org/10.1002/jcph.1583 |
Ejemplares similares
-
Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer
por: Laille, Eric, et al.
Publicado: (2015) -
CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome
por: Cannady, Ellen A., et al.
Publicado: (2015) -
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis
por: Gupta, Neeraj, et al.
Publicado: (2017) -
Lack of Impact by SCY‐078, a First‐in‐Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug‐Drug Interactions
por: Wring, Stephen, et al.
Publicado: (2018) -
Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine
por: Parasrampuria, Dolly A., et al.
Publicado: (2016)